Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) EBITDA Margin: 2023-2025

Historic EBITDA Margin for Entrada Therapeutics (TRDA) over the last 3 years, with Sep 2025 value amounting to -2,720.76%.

  • Entrada Therapeutics' EBITDA Margin fell 265570.00% to -2,720.76% in Q3 2025 from the same period last year, while for Sep 2025 it was -168.74%, marking a year-over-year decrease of 19495.00%. This contributed to the annual value of 31.02% for FY2024, which is 3446.00% up from last year.
  • Entrada Therapeutics' EBITDA Margin amounted to -2,720.76% in Q3 2025, which was down 22.98% from -2,212.31% recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' EBITDA Margin peaked at 82.25% during Q3 2023, and registered a low of -2,720.76% during Q3 2025.
  • Over the past 3 years, Entrada Therapeutics' median EBITDA Margin value was -21.16% (recorded in 2023), while the average stood at -462.48%.
  • Per our database at Business Quant, Entrada Therapeutics' EBITDA Margin skyrocketed by 20,272bps in 2024 and then crashed by 265,570bps in 2025.
  • Quarterly analysis of 3 years shows Entrada Therapeutics' EBITDA Margin stood at -21.16% in 2023, then soared by 2,147bps to 0.31% in 2024, then plummeted by 265,570bps to -2,720.76% in 2025.
  • Its EBITDA Margin was -2,720.76% in Q3 2025, compared to -2,212.31% in Q2 2025 and -82.06% in Q1 2025.